Neoepitopes as biomarkers of cartilage catabolism
- PMID: 12892070
- DOI: 10.1007/s00011-003-1177-5
Neoepitopes as biomarkers of cartilage catabolism
Abstract
Progressive degradation of articular cartilage is a central feature of arthritis and a major determinant of long term joint dysfunction. There are no treatments able to halt the progression of cartilage destruction presently available, and monitoring the benefit of potential therapies is hampered by our inability to measure the "health" of articular cartilage. Serial radiographic assessment of joint space narrowing, the current gold standard, requires measurements over a prolonged time (1-5 years) and is prone to technical difficulties. Other strategies for evaluating cartilage degradation are needed to enable both short and long term monitoring of disease progression and response to therapy. One avenue that holds promise is the use of biomarkers that accurately reflect the degradative state of the articular cartilage. Antibodies that recognise terminal amino acid sequences generated by proteolysis at specific sites in the core protein of both aggrecan and type II collagen (neoepitope antibodies) have become available in recent years. These antibodies have been invaluable for identifying the proteinases responsible for cartilage breakdown both in vitro and in vivo. The presence of neoepitope sequences generated by specific metalloenzyme cleavage of aggrecan and type II collagen correlates well with the progression of cartilage degeneration, both in vitro and in mouse models of arthritis. Preliminary results with quantitative assays of type II collagen neoepitopes suggest that they may be useful markers of joint disease in humans. Long term studies correlating neoepitope concentration with clinical and radiographic disease are now required to validate the utility of neoepitopes as surrogate markers of cartilage degeneration and joint disease.
Similar articles
-
Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration.Osteoarthritis Cartilage. 2004 Sep;12(9):720-8. doi: 10.1016/j.joca.2004.06.004. Osteoarthritis Cartilage. 2004. PMID: 15325638
-
Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.J Clin Invest. 1997 Jul 1;100(1):93-106. doi: 10.1172/JCI119526. J Clin Invest. 1997. PMID: 9202061 Free PMC article.
-
Mechanisms involved in cartilage proteoglycan catabolism.Matrix Biol. 2000 Aug;19(4):333-44. doi: 10.1016/s0945-053x(00)00078-0. Matrix Biol. 2000. PMID: 10963994 Review.
-
Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity.Arthritis Rheum. 1999 Oct;42(10):2074-84. doi: 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5. Arthritis Rheum. 1999. PMID: 10524678
-
Use of anti-neoepitope antibodies for the analysis of degradative events in cartilage and the molecular basis for neoepitope specificity.Biochem Soc Symp. 2003;(70):107-14. doi: 10.1042/bss0700107. Biochem Soc Symp. 2003. PMID: 14587286 Review.
Cited by
-
The urinary levels of CTX-II, C2C, PYD, and Helix-II increased among adults with KBD: a cross-sectional study.J Orthop Surg Res. 2019 Oct 21;14(1):328. doi: 10.1186/s13018-019-1392-6. J Orthop Surg Res. 2019. PMID: 31639015 Free PMC article.
-
Clinical monitoring in osteoarthritis: Biomarkers.Osteoarthritis Cartilage. 2022 Sep;30(9):1159-1173. doi: 10.1016/j.joca.2021.04.019. Epub 2021 Sep 16. Osteoarthritis Cartilage. 2022. PMID: 34536529 Free PMC article.
-
Molecular serum markers of liver fibrosis.Biomark Insights. 2012;7:105-17. doi: 10.4137/BMI.S10009. Epub 2012 Jul 23. Biomark Insights. 2012. PMID: 22872786 Free PMC article.
-
Insights into the present and future of cartilage regeneration and joint repair.Cell Regen. 2022 Feb 2;11(1):3. doi: 10.1186/s13619-021-00104-5. Cell Regen. 2022. PMID: 35106664 Free PMC article. Review.
-
The role of aggrecan in normal and osteoarthritic cartilage.J Exp Orthop. 2014 Dec;1(1):8. doi: 10.1186/s40634-014-0008-7. Epub 2014 Jul 16. J Exp Orthop. 2014. PMID: 26914753 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
